Pleconaril, a new aniviral drug with activity against picornavirus
Reina, J.; Ballesteros, F.
Revista Espanola de Quimioterapia Publicacion Oficial de la Sociedad Espanola de Quimioterapia 13(3): 257-262
2000
ISSN/ISBN: 0214-3429 PMID: 11086273 Document Number: 515804
Document emailed within 1 workday
Related Documents
Ivanoff, L.A.; Cordova, A.A.; Petteway, S.R.; Korant, B.D. 1985: Biochemistry and structure of picornavirus proteases Progress in Clinical and Biological Research 180: 255-256Hantschel, H.; Liebermann, H.; Thalmann, G. 1985: Production of picornavirus concentrates using ultrafiltration Archiv für Experimentelle Veterinarmedizin 39(5): 723-729
Wang, H.; Xie, G-Cheng.; Duan, Z-Jun. 2014: Current research on picornavirus 3C protease Bing du Xue Bao 30(5): 579-586
Holzinger, E.A.; Kahn, D.E. 1970: Pathologic features of picornavirus infections in cats American Journal of Veterinary Research 31(9): 1623-1630
Mattson, J.M.; Vorhies, M.W.; Reed, D.E. 1974: Pathogenic properties of six bovine picornavirus isolates in mice American Journal of Veterinary Research 35(12): 1545-1548
Reavy, B.; Pullin, J.S.; Moore, N.F. 1983: Translational inhibition of heat-shock induced gene expression in picornavirus-infected Drosophila melanogaster cells Microbios 38(152): 91-98
Molnár, J. 1999: Reversal of drug resistance in bacteria and tumor cells. (Drug research based on computer-predicted activity) Orvosi Hetilap 140(39): 2155-2160
Boselli, G. 1972: Clinical study of the activity and tolerance of hydropropizine, a drug with antitussive activity Minerva Medica 63(51): 2782-2788
Craighead, J.E.; Huber, S.A.; Sriram, S. 1990: Animal models of picornavirus-induced autoimmune disease: their possible relevance to human disease Laboratory Investigation; A Journal of Technical Methods and Pathology 63(4): 432-446
Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. 1995: 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity Journal of Pharmacology and Experimental Therapeutics 274(1): 329-336
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Arushanian, E.B. 2002: Drug chronotropic activity Eksperimental'naia i Klinicheskaia Farmakologiia 65(1): 75-76
Carter, W.H.; Wampler, G.L.; Stablein, D.M.; Campbell, E.D. 1982: Drug activity and therapeutic synergism in cancer treatment Cancer Research 42(8): 2963-2971
Roch-Arveiller, M.; Pham-Huy, D.; Muntaner, O.; Maman, L.; Giroud, J.P. 1987: Drug activity "in vitro" and "in vivo" on leucocyte chemotaxis Biomedicine and PharmacoTherapy 41(6): 321-328
Mikhaĭlitsyn, F.S.; Lebedeva, M.N.; Gitsu, G.A.; Lychko, N.D. 2006: Acute toxicity and antihymenolepiac activity of the new drug feliram Meditsinskaia Parazitologiia i Parazitarnye Bolezni 4: 59
Ruffmann, R.; Sartani, A. 1987: Flavoxate, a drug with smooth muscle relaxing activity Drugs under Experimental and Clinical Research 13(1): 57-62
Watson, E.L.; Tolman, K.G. 1973: Calcium ATPase activity in drug-induced osteomalacia Research Communications in Chemical Pathology and Pharmacology 6(3): 1079-1082
Guo, Z.-R. 2010: Strategy of molecular drug design: activity and druggability Yao Xue Xue Bao 45(5): 539-547
Scala, S.M.; Schneider, P.J.; Smith, G.L.; Bourret, J.A. 1986: Activity analysis of pharmacy-directed drug-administration technicians American Journal of Hospital Pharmacy 43(7): 1702-1706
Zajaczkowska-Białowas, L.; Nowicka, J.; Kuc, B.; Sibora, P. 1989: Studies of lysozyme activity in the saliva of workers in the drug industry Medycyna Pracy 40(5): 321-327